{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:45:32Z","timestamp":1791812732489,"version":"4.3.4"},"reference-count":13,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    There are limited antimicrobial options for the treatment of carbapenem-resistant\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (CRAB). Sulbactam-durlobactam was recently approved for the treatment of CRAB in patients 18 years and older. However, CRAB infections can have mortality rates up to 80% in the intensive care unit. We describe the successful novel use of sulbactam-durlobactam in a pediatric patient using available adult pharmacokinetic data and preliminary pediatric dosing suggestions from a phase 1b trial.\n                  <\/jats:p>","DOI":"10.5863\/jppt-25-00096","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:50:57Z","timestamp":1791809457000},"page":"666-670","source":"Crossref","is-referenced-by-count":0,"title":["Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter baumannii in a Child: A Novel Application of Adult Pharmacokinetics"],"prefix":"10.5863","volume":"31","author":[{"given":"Leah","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Center for Healthcare Quality and Analytics (LR), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Resendiz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (BB, KR), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Blowey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (BB, KR), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"St. Cyr","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases (JM, GS), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McAteer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases (JM, GS), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"12","key":"JPPT-25-00096-b01","series-title":"Curr Infect Dis Rep","first-page":"46","article-title":"Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat","volume":"21","author":"Butler","year":"2019","unstructured":"Butler DA, Biagi M, Tan X, et al. Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21(12):46."},{"key":"JPPT-25-00096-b02","series-title":"Feigin and Cherry\u2019s Textbook of Pediatric Infectious Diseases","first-page":"1124","article-title":"Acinetobacter","author":"Correa","year":"2019","unstructured":"Correa A. Acinetobacter. In: Cherry JD, Harrison GJ, Kaplan SL, eds. Feigin and Cherry\u2019s Textbook of Pediatric Infectious Diseases. 8th ed. Elsevier; 2019:1124\u20131128.e4."},{"key":"JPPT-25-00096-b03","series-title":"Pediatr Infect Dis J","first-page":"685","article-title":"Investigation and control of an outbreak of imipenem-resistant Acinetobacter baumannii infection in a pediatric intensive care unit","volume":"31","author":"Hong","year":"2012","unstructured":"Hong KB, Oh HS, Song JS, et al. Investigation and control of an outbreak of imipenem-resistant Acinetobacter baumannii infection in a pediatric intensive care unit. Pediatr Infect Dis J. 2012;31:685\u2013690."},{"issue":"1","key":"JPPT-25-00096-b04","series-title":"J Hosp Infect","first-page":"27","article-title":"Aerators as a reservoir of Acinetobacter junii: an outbreak of bacteraemia in paediatric oncology patients","volume":"44","author":"Kappstein","year":"2000","unstructured":"Kappstein I, Grundmann H, Hauer T, Niemeyer C. Aerators as a reservoir of Acinetobacter junii: an outbreak of bacteraemia in paediatric oncology patients. J Hosp Infect. 2000;44(1):27\u201330."},{"issue":"4","key":"JPPT-25-00096-b05","series-title":"Germs","first-page":"381","article-title":"Acinetobacter baumannii: a known pathogen, a new problem","volume":"13","author":"Monteiro","year":"2023","unstructured":"Monteiro RC, Malta RCR, Rodrigues GL, et al. Acinetobacter baumannii: a known pathogen, a new problem. Germs. 2023;13(4):381\u2013384."},{"key":"JPPT-25-00096-b06","series-title":"Antimicrobial resistance","article-title":"AR Threats Report. 2019","year":"2019","unstructured":"Centers for Disease Control and Prevention (CDC). Antimicrobial resistance. 2019 AR Threats Report. 2019. Accessed May 12, 2025. https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html"},{"key":"JPPT-25-00096-b07","series-title":"Clin Infect Dis","first-page":"ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024;ciae403."},{"key":"JPPT-25-00096-b08","article-title":"XACDURO (sulbactam for injection; durlobactam for injection) [package insert]","year":"2023","unstructured":"XACDURO (sulbactam for injection; durlobactam for injection) [package insert]. Waltham, MA: La Jolla Pharmaceutical Company; 2023."},{"issue":"9","key":"JPPT-25-00096-b09","series-title":"Lancet Infect Dis","first-page":"1072","article-title":"Efficacy and safety of Sulbactam\u2013Durlobactam versus Colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (attack)","volume":"23","author":"Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of Sulbactam\u2013Durlobactam versus Colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (attack). Lancet Infect Dis. 2023;23(9):1072\u20131084."},{"key":"JPPT-25-00096-b10","article-title":"A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection","unstructured":"A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection. Clinicaltrials.gov. Accessed July 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06801223"},{"issue":"2","key":"JPPT-25-00096-b11","series-title":"J Pediatric Infect Dis Soc","first-page":"piaf004","article-title":"Suggested dosing of select \u0392-lactam agents for the treatment of antimicrobial-resistant Gram-negative infections in children","volume":"14","author":"Lockowitz","year":"2025","unstructured":"Lockowitz CR, Hsu AJ, Chiotos K, et al. Suggested dosing of select \u0392-lactam agents for the treatment of antimicrobial-resistant Gram-negative infections in children. J Pediatric Infect Dis Soc. 2025;14(2):piaf004."},{"key":"JPPT-25-00096-b12","series-title":"Front Microbiol","first-page":"709974","article-title":"Durlobactam, a new diazabicyclooctane \u03b2-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam","volume":"12","author":"Shapiro","year":"2021","unstructured":"Shapiro AB, Moussa SH, McLeod SM, et al. Durlobactam, a new diazabicyclooctane \u03b2-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam. Front Microbiol. 2021;12:709974."},{"issue":"suppl 2","key":"JPPT-25-00096-b13","series-title":"Clin Infect Dis","first-page":"S202","article-title":"The pharmacokinetics\/pharmacodynamic relationship of Durlobactam in combination with sulbactam in in vitro and in vivo infection model systems versus Acinetobacter baumannii-calcoaceticus complex","volume":"76","author":"O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell JP, Bhavnani SM. The pharmacokinetics\/pharmacodynamic relationship of Durlobactam in combination with sulbactam in in vitro and in vivo infection model systems versus Acinetobacter baumannii-calcoaceticus complex. Clin Infect Dis. 2023;76(suppl 2):S202\u2013S209."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/5\/article-p666.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/5\/article-p666.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/5\/article-p666.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:50:57Z","timestamp":1791809457000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/5\/article-p666.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":13,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-00096","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}